Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Cools

Showing results (81-90 of 184) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylateHans Prenen, Jan Cools, Nicole Mentens, et al.
Blood|April 5, 2003
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessAmy D Klion, Pierre Noel, Cem Akin, et al.
Frontiers in Immunology|October 16, 2018
The Long Non-coding RNA <i>Flatr</i> Anticipates Foxp3 Expression in Regulatory T CellsAleksandra Brajic, Dean Franckaert, Oliver Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationBarbara Dewaele, Bartosz Wasag, Jan Cools, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2006
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentElizabeth H Stover, Jing Chen, Cedric Folens, et al.
Genes, Chromosomes & Cancer|July 12, 2002
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumorJan Cools, Iwona Wlodarska, Riet Somers, et al.
Blood|April 29, 2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutantEls Lierman, Cedric Folens, Elizabeth H Stover, et al.
Genes, Chromosomes & Cancer|March 28, 2003
A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 geneEva Maria Murga Penas, Jan Cools, Petra Algenstaedt, et al.
Cancer Research|April 6, 2006
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABLMyriam Adam, Vanda Pogacic, Marina Bendit, et al.
Haematologica|March 9, 2010
ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusionsKatrien Van Roosbroeck, Jan Cools, Daan Dierickx, et al.
Pageof 19

Showing results (81-90 of 184) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylateHans Prenen, Jan Cools, Nicole Mentens, et al.
Blood|April 5, 2003
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessAmy D Klion, Pierre Noel, Cem Akin, et al.
Frontiers in Immunology|October 16, 2018
The Long Non-coding RNA <i>Flatr</i> Anticipates Foxp3 Expression in Regulatory T CellsAleksandra Brajic, Dean Franckaert, Oliver Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationBarbara Dewaele, Bartosz Wasag, Jan Cools, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2006
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentElizabeth H Stover, Jing Chen, Cedric Folens, et al.
Genes, Chromosomes & Cancer|July 12, 2002
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumorJan Cools, Iwona Wlodarska, Riet Somers, et al.
Blood|April 29, 2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutantEls Lierman, Cedric Folens, Elizabeth H Stover, et al.
Genes, Chromosomes & Cancer|March 28, 2003
A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 geneEva Maria Murga Penas, Jan Cools, Petra Algenstaedt, et al.
Cancer Research|April 6, 2006
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABLMyriam Adam, Vanda Pogacic, Marina Bendit, et al.
Haematologica|March 9, 2010
ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusionsKatrien Van Roosbroeck, Jan Cools, Daan Dierickx, et al.
Pageof 19